Ceryx has fortified its Board of Directors with the addition of Mark Strong, an esteemed figure in the medical devices sector. Strong’s extensive global leadership experience includes senior roles at Abbott, Boston Scientific, and HeartWare, as well as his recent position as CEO of Heart Failure Solutions. His expertise in developing and commercialising innovative cardiovascular technologies is expected to significantly benefit Ceryx.
This strategic appointment coincides with a critical juncture for Ceryx, following the successful completion of a first-in-human trial for its pioneering cardiac rhythm management device. Designed to enhance the efficiency of the failing heart and activate its intrinsic repair mechanisms, this technology could potentially revolutionise heart failure treatment.
Dr Stuart Plant, CEO of Ceryx Medical, expressed enthusiasm about Strong’s appointment, stating: “I am delighted to welcome Mark to the Board as a Non-Executive Director. He brings a wealth of experience and insight to Ceryx. Attracting someone of Mark’s calibre is a strong endorsement of our technology and our mission.”
Mark Strong commented on his new role, saying: “Very few devices have captured my attention the way this one has. Ceryx technology has the potential to meaningfully improve cardiac output and support cardiac recovery in heart failure patients. Stuart and the team have done exceptional work, and I’m pleased to support this next phase of growth.”
Heart failure remains a significant health challenge, affecting over 20 million individuals across Europe and the US, and is the leading cause of hospitalisation for those over 65. The prognosis is grim, with approximately half of the diagnosed patients succumbing within five years.
Dr Plant added, “This is an exceptionally exciting period for the company. We are confident that our technology can change the outlook for heart failure patients. We also believe our core platform has potential applications in other conditions, including hypertension and spinal cord injuries, giving us the foundations for a strong future pipeline of breakthrough therapies.”
Ceryx Medical has garnered interest from partners and investors both domestically and internationally, with support from prominent MedTech investors such as BGF, ParkWalk, and the Development Bank of Wales.
